Peri-implant mucositis Oral Health
Conditions
Interventions
The study includes a cohort of 40 patients equally divided into one of the two groups – A and B. Participants will be selected from patients of the Department of Periodontology of the Victor Babes Uni
Group B [Placebo (control)]: topical application of a placebo gel, similar in aspect and consistency with the test gel.
Post-application instructions for groups A and B were as follows: gentle brushi
Sponsors
MegaGen Dental Implant Romania
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age =18 years 2. Absence of relevant medical conditions 3. Partially edentulous subjects with healthy or treated periodontal conditions enrolled in a regular supportive care program 4. Peri-implant mucositis defined as =1 implant site with the presence of BoP and absence of radiographic bone loss compared with a previous radiograph (Renvert, et al., 2018) 5. Implant in function for =1 year 6. Full-Mouth Plaque Score (FMPS) =25 7. Full-Mouth Bleeding Score (FMBS) =25
Exclusion criteria
Exclusion criteria: 1. Uncontrolled medical conditions 2. Pregnant or lactating females 3. Tobacco smoking =10 cigarettes/day 4. Untreated periodontal conditions 5. Removable implant -retained prosthesis or other chronic systemic medications that could interfere with the study outcomes 6. Use of antibiotics in the past 3 months 7. Subjects treated for =2 weeks with any medication known to affect soft tissue conditions (e.g. phenytoin, calcium antagonists, cyclosporin, blood thinners and nonsteroidal anti-inflammatory drugs) within 1 month of the baseline examination 8. Failure to sign written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Implant pocket probing depth (PPD) measured from the mucosal margin to the bottom of the probable pocket and evaluated at six sites per implant (i.e., disto-buccal, mid-buccal, mesio-buccal, mesio-lingual/palatal, mid-lingual/palatal, disto-lingual/palatal) at the clinical baseline evaluation (before therapy) and the 3 and 6-month re-evaluations | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline, 3 and 6 months: 1. Full mouth bleeding score (FMBS) recorded at six sites per tooth: mesiobuccal, midbuccal, distobuccal, disto-oral, midoral, and mesio-oral 2. Mean full mouth plaque score (FMPS) evaluated at six sites per tooth at 30 seconds from the survey 3. Overall bleeding index (BOP) evaluated at six sites per tooth/implant at 30 seconds from the survey 4. Number of the following five keystone bacterial pathogens measured using molecular genetic analysis, micro–IDent A Test at baseline and 3 months: 4.1. Aggregatibacter actinomycetemcomitans 4.2. Porphyromonas gingivalis 4.3. Prevotella intermedia 4.4. Tannerella forsythia 4.5. Treponema denticola | — |
Countries
Romania
Contacts
Public ContactIoana Ilyes
Outcome results
None listed